unknown
Stage
About
Diasome Pharmaceuticals is developing liver-targeted metabolic therapies, including insulin formulations that improve glycemic control and reduce hypoglycemia risk in diabetes patients by delivering drugs directly to the portal-hepatic region.
Explore Diasome Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.